Spherics, Inc., an emerging pharmaceutical company focused on applying its oral drug delivery platform to develop products with improved therapeutic profiles, today announced that it has successfully completed its Series C round of financing, raising $26.4M. The proceeds from this financing will be used to advance the Company’s pipeline of products based on its proprietary drug delivery technologies, as well as enhance its commercialization and business development capabilities.
Spherics Secures $26.4M Financing to Advance Clinical Programs Based on Proprietary Oral Drug Delivery Platform
Serono and Syntonix Sign Worldwide Agreement to Develop and Commercialize an Inhaleable Interferon-Beta Therapy for Multiple Sclerosis
Serono (virt-x: SEO and NYSE: SRA) and Syntonix Pharmaceuticals Inc. announced today that they have entered into an agreement under which Serono has licensed worldwide exclusive rights to Syntonix’ TransceptorTM and SynFusionTM technologies for the development and commercialization of interferon-beta:Fc products.
Vitex Closes Merger with Panacos Pharmaceuticals $20 Million Financing Also Closed and Funded
V.I. Technologies, Inc. (Nasdaq: VITX) (“Vitex” or “the Company”), a biotechnology company dedicated to developing the next generation of anti-infective
therapeutics, today announced that it has closed its previously announced merger with Panacos Pharmaceuticals. Under the terms of the merger, Vitex will issue approximately 227.5 million shares to Panacos stockholders to acquire all of the outstanding shares of Panacos.
Plexxikon, Wyeth PPAR Deal: Up to $372M In Diabetes Bid (BioWorld Today)
If there’s anxiety lingering after the FDA’s summer ruling about potential cancer toxicity with peroxisome proliferator-activated receptors (PPARs), you wouldn’t know it from Wyeth – which entered a potential $372 mil- lion deal with Plexxikon Inc. to develop treatments for diabetes and metabolic disorders.
Panacos, Vitex Merging In $27M Stock Exchange, Plus Milestones (BioWorld Today)
Bringing together two infectious disease pipelines, Panacos Pharmaceuticals Inc. entered a definitive merger agreement with V.I. Technologies Inc., also called Vitex.
Plexxikon Gets $15M Investment For Diabetes Drug Development (BioWorld Today)
Plexxikon Inc. raised $15 million in venture financing to complete a Series B extension round.
Dynogen's GI, GU Products To Benefit From $50M Round (BioWorld Today)
In its largest financing to date, Dynogen Pharmaceuticals Inc. secured $50 million in a Series B round, enabling it to build its pipeline and advance its two clinical com- pounds.
Dynogen Pharma gets $50M round (TheDeal.com)
Boston-based Dynogen Pharmaceuticals Inc. said Monday, April 19, it had secured a $50 million B round of financing that it will use to further develop its neuroscientific approach to treating genitourinary and gastrointestinal disorders.
